BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27373200)

  • 1. In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.
    Ami D; Lavatelli F; Rognoni P; Palladini G; Raimondi S; Giorgetti S; Monti L; Doglia SM; Natalello A; Merlini G
    Sci Rep; 2016 Jul; 6():29096. PubMed ID: 27373200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
    Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
    Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.
    Imperlini E; Gnecchi M; Rognoni P; Sabidò E; Ciuffreda MC; Palladini G; Espadas G; Mancuso FM; Bozzola M; Malpasso G; Valentini V; Palladini G; Orrù S; Ferraro G; Milani P; Perlini S; Salvatore F; Merlini G; Lavatelli F
    Sci Rep; 2017 Nov; 7(1):15661. PubMed ID: 29142197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
    Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
    PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.
    Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F
    FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis.
    Lavatelli F; Mazzini G; Ricagno S; Iavarone F; Rognoni P; Milani P; Nuvolone M; Swuec P; Caminito S; Tasaki M; Chaves-Sanjuan A; Urbani A; Merlini G; Palladini G
    J Biol Chem; 2020 Dec; 295(49):16572-16584. PubMed ID: 32952127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin light chain amyloid aggregation.
    Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
    Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
    Renz M; Torres R; Dolan PJ; Tam SJ; Tapia JR; Li L; Salmans JR; Barbour RM; Shughrue PJ; Nijjar T; Schenk D; Kinney GG; Zago W
    Amyloid; 2016 Sep; 23(3):168-177. PubMed ID: 27494229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.
    Ward JE; Ren R; Toraldo G; Soohoo P; Guan J; O'Hara C; Jasuja R; Trinkaus-Randall V; Liao R; Connors LH; Seldin DC
    Blood; 2011 Dec; 118(25):6610-7. PubMed ID: 21998211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.
    Blancas-Mejía LM; Hammernik J; Marin-Argany M; Ramirez-Alvarado M
    J Biol Chem; 2015 Feb; 290(8):4953-4965. PubMed ID: 25538238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis.
    Morgan GJ
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34208058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
    Zhang C; Huang X; Li J
    Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
    Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
    J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
    Morgan GJ; Kelly JW
    J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability.
    Pradhan T; Annamalai K; Sarkar R; Huhn S; Hegenbart U; Schönland S; Fändrich M; Reif B
    J Biol Chem; 2020 Dec; 295(52):18474-18484. PubMed ID: 33093170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of single point mutations in a form of systemic amyloidosis.
    Bhavaraju M; Hansmann UH
    Protein Sci; 2015 Sep; 24(9):1451-62. PubMed ID: 26105812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept.
    Ramirez-Alvarado M; Barnidge DR; Murray DL; Dispenzieri A; Marin-Argany M; Dick CJ; Cooper SA; Nasr SH; Ward CJ; Dasari S; Jiménez-Zepeda VH; Leung N
    Am J Hematol; 2017 Jun; 92(6):536-541. PubMed ID: 28295502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
    Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
    Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.
    Oberti L; Rognoni P; Barbiroli A; Lavatelli F; Russo R; Maritan M; Palladini G; Bolognesi M; Merlini G; Ricagno S
    Sci Rep; 2017 Dec; 7(1):16809. PubMed ID: 29196671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in Protein Concentration Dependence for Nucleation and Elongation in Light Chain Amyloid Formation.
    Blancas-Mejía LM; Misra P; Ramirez-Alvarado M
    Biochemistry; 2017 Feb; 56(5):757-766. PubMed ID: 28074646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.